Body weight changes associated with insulin therapy: A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled phase III trials

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2508-2510

  Hollander, Priscilla A ^a   Krasner, Alan ^b   Klioze, Sol ^b   Schwartz, Pamela ^b   Duggan, William ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME; WEIGHT CHANGE;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; NORTH AMERICA; RETROSPECTIVE STUDIES; SOUTH AMERICA;

EID: 35148897704     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2083     Document Type: Article

References (15)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JPH, Pinkney JH: Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 82:280-284, 2006
3. International Obesity Task Force: Diabetes atlas [article online], 2003. 2nd ed. International Diabetes Federation, Brussels. Available from http://www.eatlas.idf.org/Obesity_and_type_2_diabetes. Accessed 9 October 2006
4. Purnell JO, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the Diabetes Control and Complications Trial. JAMA 280:140-146, 1998
5. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes 26 (Suppl. 3):S18-S24, 2002
6. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, the UK Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study. Diabetes Care 25:330-336, 2002
7. Quattrin T, Belanger A, Bohannon NJV, Schwartz SL, the Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 27:2622-2627, 2004
8. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC, the Inhaled Insulin Phase III Type 1 Diabetes Study Group: Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects. Diabetes Care 28:1630-1635, 2005
9. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W, the Inhaled Human Insulin Type 1 Diabetes Study Group: Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 30:579-585, 2007
10. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson J-L, Levin SR, the Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 27:2356-2362, 2004
11. Rosenstock J, Foyt H, Klioze S, Ogawa M, St Aubin L, Duggan W: Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM) (Abstract). Diabetes 55 (Suppl. 1):A26, 2006
12. Odegard PS, Capoccia KL: Inhaled insulin: Exubera. Ann Pharmacother 39:843-853, 2005
13. Edgerton DS, Neal DW, Scott M, Glass D, Bowen L, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, Cherrington AD: Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54:1164-1170, 2005
14. Van Gaal LF, Wauters MA, De Leeuw IH: The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 21 (Suppl. 1):S5-S9, 1997
15. Jung R: Obesity as a disease. Br Med Bull 53:307-321, 1997